Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Clinical Cancer Research|2024Cited by 42
Circulating proteins to predict COVID-19 severityChen‐Yang Su, Ieisha Scott, Sirui Zhou et al.|Scientific Reports|2023Cited by 19
Circulating proteins to predict adverse COVID-19 outcomesChen‐Yang Su, Ieisha Scott, Xiaoqing Xue et al.|medRxiv|2021Cited by 4
Supplementary Figure 2 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Unknown|2024Cited by 0
Supplementary Table 5 from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I TrialEdwin R. Parra, Cara Haymaker, Jiexin Zhang et al.|Unknown|2024Cited by 0